The Value-Based Care Trap Part 1: What We Stand to Gain (and Lose)
Value based care (VBC) is the new magic word in healthcare strategy meetings. CMS, payers, and consultants all promise better quality at lower cost if we just “align incentives” and “focus on outcomes.” For small orthotics and prosthetics (O&P) practices, that pitch is both an opportunity and a potential trap.
In this first blog, I’ll frame what VBC really means for O&P, what we genuinely stand to gain, and where the ground is already shifting under our feet.
What value-based care actually is in O&P terms
On paper, value-based care ties payment to outcomes, equity, and total cost of care instead of raw volume. Avalere Health’s white paper on VBC and O&P gives our profession a clear theoretical role: payers want models that reward prevention, care coordination, and patient centered function—not just devices.
For O&P, that sounds promising. Dobson–DaVanzo’s work shows that when patients receive appropriate prosthetic and orthotic services, their 15–18month total Medicare costs are similar or lower, and their quality of life improves, compared with similar patients who do not receive those services. In other words, the combination of O&P care plus the right devices already meets the textbook definition of “value.”
The catch: in almost all current VBC models, O&P is not the one holding the contract or the risk. Hospitals, large physician groups, or conveners own the bundle and control the purse strings; we show up on their spreadsheets as a downstream cost.
The upside: what O&P stands to gain
1. Recognition for the value you already create
Dobson–DaVanzo and follow-ups summaries make a strong case that O&P services reduce downstream spending by keeping patients mobile and in the community instead of in hospitals and nursing facilities. Avalere builds on this, arguing that integrating O&P into episodes (joint replacement, chronic disease management, etc.) could help health systems hit their quality and cost targets.
If local leaders actually see and believe that story, O&P moves from “nice-to-have product cost” to “strategic lever for episode success.”
2. Earlier and deeper integration in the care team
CMS’s VBC materials emphasize person-centered, coordinated care that addresses the full set of patient needs. Avalere points out that O&P providers are often the clinicians who know the most about a patient’s day-to-day functional reality, but we’re rarely at the planning table.
A value-based frame gives you a language to argue for earlier involvement: before falls, before skin breakdown, before deconditioning—when good device decisions and training can still change the trajectory.
3. Potential upside when outcomes are measured
In principle, if your patients fall less, walk farther, and avoid rehospitalization, you should share in the savings from lower acute and post acute utilization. For practices that already run tight clinical processes and track outcomes, VBC could turn “doing the right thing” into measurable financial upside instead of just extra unpaid work.
The downside: where the trap starts to close
All of that is real upside. But the same features that make O&P valuable also create risk once you step into a formal VBC world:
Outcomes depend on factors you don’t fully control: therapy intensity, physician follow-up, patient adherence, and social determinants.
Episode targets and utilization rules are usually designed around hospitals and physicians, not small, device based specialties.
If leadership sees you as a flexible cost center instead of a core clinical partner, the easiest way to “optimize the bundle” is to squeeze or internalize O&P.
That’s the beginning of the value-based care trap: taking on more expectations and responsibility for outcomes in a system where your value is poorly understood and your role in the money flow is weak.
In Part 2, we’ll dig into the hidden cost of change, the perceptions we have to overcome, and a pragmatic way for small O&P practices to benefit from VBC without getting burned.